Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Authors:
- Paul Andrei NegruPNPaul Andrei Negru
- Andrei-Flavius RaduARAndrei-Flavius Radu
- Cosmin Mihai VesaCosmin Mihai Vesa
- Tapan BehlTapan Behl
- Mohamed M. Abdel-DaimMohamed M. Abdel-Daim
- Aurelia Cristina NechiforANAurelia Cristina Nechifor
- Laura EndresLELaura Endres
- Manuela StoicescuMSManuela Stoicescu
- Bianca PascaBianca Pasca
- Delia Mirela TitDelia Mirela Tit
- Simona Gabriela BungauSimona Gabriela Bungau
Open Access
- 4 February 2022
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 147, 112700
Abstract
No abstract availableKeywords
This publication has 130 references indexed in Scilit:
- Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy TrialsClinical Pharmacokinetics, 2016
- Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human PrimatesOpen Forum Infectious Diseases, 2015
- mRNA-based therapeutics — developing a new class of drugsNature Reviews Drug Discovery, 2014
- Practical pharmacokinetics: what do you really need to know?Archives of Disease in Childhood - Education & Practice Edition, 2014
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal modelAntiviral Research, 2014
- Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse modelAntiviral Research, 2014
- Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research, 2013
- Pharmacokinetic drug-drug interaction and their implication in clinical management2013
- Drug-drug interactions contributing to QT prolongation in cardiac intensive care unitsJournal of Critical Care, 2013
- Human Liver Aldehyde Oxidase: Inhibition by 239 DrugsThe Journal of Clinical Pharmacology, 2004